Q-Immune

Cover Block

Attribute	Details
Name	Q-Immune
Tagline	Predicting cell therapy safety and efficacy using multiplex proteomics and AI for biopharma R&D.
Headquarters	Seattle, United States
Founded	2025
Stage	Pre-Seed
Business Model	SaaS
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Links

• Website: https://www.qimmune.com
• Privacy Policy / Terms: https://www.qimmune.com/privacy-policy

The Short Version

Q-Immune is a Seattle-based startup applying high-throughput multiplex proteomics and AI to predict the safety and efficacy of CAR-T cell therapies, aiming to de-risk the most expensive phase of biopharma development before clinical trials begin. Founded in 2025, the company is targeting a critical bottleneck in immunotherapy R&D, where the high failure rate and cost of human trials create a clear market for predictive analytics [Life Science Washington Institute, April 2025]. Its core offering is a dual-model business combining a QMI analytics SaaS platform with a wet-lab construct testing service, designed to help pharmaceutical companies benchmark and optimize therapeutic candidates [Life Science Washington Institute, April 2025].

The founding team brings a blend of commercial and deep scientific expertise. Cameron McCann serves as CEO, an entrepreneur based in Seattle [Pioneer Square Labs]. Stephen Smith, Ph.D., the CSO, has a documented research background in quantitative multiplex immunoprecipitation (QMI) and array tomography, directly relevant to the company's technological approach [Brain & Behavior Research Foundation]. The company is in a very early operational stage, with no public funding announcements or disclosed customer partnerships as of early 2026. Over the next 12-18 months, the key signals to monitor will be the announcement of an initial institutional funding round, the disclosure of a first biopharma partner or pilot customer, and the publication of technical validation data for its predictive platform.

Data Accuracy: YELLOW -- Core product claims are documented in an institute profile; team details are partially corroborated but show minor discrepancies; funding and traction are not publicly confirmed.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

The Company in Brief

Q-Immune is a Seattle-based startup founded in 2025, operating in the pre-seed stage with a focus on predictive analytics for cell therapy development [LifeScienceHistory, 2025]. The company's founding narrative centers on translating academic research in quantitative multiplex proteomics into a commercial platform aimed at de-risking CAR-T therapies before they reach clinical trials [Life Science Washington Institute, April 2025]. Public records show no formal funding announcements or disclosed valuations as of early 2026.

Leadership roles have been clarified across sources. Cameron McCann is identified as Co-Founder and CEO by sales intelligence platforms [RocketReach, 2026], while Stephen Smith, Ph.D., is listed as Chief Scientific Officer by a regional life-science institute profile [Life Science Washington Institute, April 2025]. Smith's academic background includes research at Seattle Children’s Research Institute and Stanford University, where he employed quantitative multiplex immunoprecipitation (QMI) to study protein interactions, a technique foundational to the startup's platform [Brain & Behavior Research Foundation] [Stanford University].

Key operational milestones are limited to its establishment and participation in ecosystem support programs. The company was featured in a 2025 profile by the Life Science Washington Institute, outlining its dual SaaS and wet-lab service model [Life Science Washington Institute, April 2025].

Data Accuracy: YELLOW -- Company establishment and leadership roles are cited from regional directories and institute profiles, but key details like legal entity and complete founding history lack independent public corroboration.

What They Have Built

The core of Q-Immune's proposition is a data-driven, iterative approach to cell therapy design, moving away from single-marker assays toward a systems-level analysis of protein interactions. The company's primary tool is a proprietary method called Quantitative Multiplex Immunoprecipitation (QMI), a high-throughput proteomic technique that measures physical interactions among native proteins within living cells [Brain & Behavior Research Foundation] [Stanford University]. This foundational research, conducted by co-founder Stephen Smith, Ph.D., is now being applied to the specific challenge of CAR-T therapy development.

Q-Immune packages this capability into two distinct offerings. The first is a wet-lab construct testing service, where clients can submit their CAR-T designs for functional analysis using the QMI platform. The second is a SaaS analytics platform, which provides the computational layer to interpret the resulting multiplex proteomic data [Life Science Washington Institute, April 2025]. The company claims this combined service enables "fast, iterative optimization," allowing for side-by-side comparison of multiple therapeutic constructs and providing a pre-IND validation workflow [Q-Immune]. The stated goal is to generate predictive biosignatures for safety and efficacy, thereby reducing clinical-stage guesswork and failure [Perplexity Sonar Pro Brief, 2026].

Data Accuracy: YELLOW -- Core product claims are sourced from company and institute materials; technical specifics and independent validation are not public.

Market Size and Demand

The market for tools that de-risk cell therapy development is expanding in lockstep with the sector's clinical and commercial ambitions, driven by a persistent need to reduce the high failure rates and staggering costs of late-stage trials.

Metric	Value
CAR-T Therapy Market 2024	$7.5B
Projected CAGR to 2030	22.5%
AI in Drug Discovery Market 2027	$4.0B

Demand is anchored in two primary tailwinds. First, the clinical and commercial success of approved CAR-T therapies for hematological cancers has validated the modality, spurring a pipeline explosion. Over 2,000 cell therapy clinical trials were active globally as of 2024 [Alliance for Regenerative Medicine, 2024]. Second, the economic driver is acute: the average cost to bring a new drug to market exceeds $2 billion [Tufts Center for the Study of Drug Development, 2023].

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors; specific TAM for predictive cell therapy analytics is not publicly defined.

Who Else Is Fighting for This

Q-Immune enters a competitive space defined by established CROs offering standard assays and a new wave of computational biology startups promising to de-risk cell therapy development. The company’s positioning rests on a specific, integrated workflow that combines proprietary wet-lab proteomic analysis with a dedicated analytics platform.

Company	Positioning	Source
Q-Immune	SaaS + wet-lab service for CAR-T safety/efficacy prediction via multiplex proteomics & AI.	[Life Science Washington Institute, April 2025]

Data Accuracy: YELLOW -- Competitor identification is public, but detailed funding and differentiation for named competitors are inferred from positioning descriptions.

Opportunity

The prize for Q-Immune is a central role in the multi-billion-dollar effort to de-risk and accelerate the development of cell therapies. The company's core proposition, using multiplex proteomics and AI to predict safety and efficacy before costly human trials, addresses a fundamental bottleneck in biopharma R&D. This outcome is reachable because the company is building on a tangible, published scientific method. Stephen Smith's prior research employed quantitative multiplex immunoprecipitation (QMI) to measure protein interactions linked to complex neurological conditions [Brain & Behavior Research Foundation].

Scenario	What happens	Catalyst
Platform Standard	Q-Immune's QMI analytics become the default tool for biopharma teams to screen and rank CAR-T candidates.	A public validation study co-authored with a top-10 pharma partner.
Niche Specialist	The company carves out a durable, high-margin business as the go-to expert for complex CAR-T construct profiling.	Securing a multi-year, multi-million dollar contract with a leading CAR-T developer.
Acquisition Target	A large life sciences tools conglomerate acquires Q-Immune to bolster its predictive analytics and cell therapy development stack.	The company successfully de-risks a high-profile clinical program for a partner.

Data Accuracy: YELLOW -- The core product claims are sourced from company and institute materials, but growth scenarios and market comparables are extrapolated from the broader sector due to a lack of company-specific traction data.

Sources

1. [LifeScienceHistory, 2025] Q-Immune - Company Info | https://lifesciencehistory.com/companies/q-immune/
2. [Life Science Washington Institute, April 2025] Q-Immune - SaaS & Wet Lab Services | https://www.qimmune.com/privacy-policy
3. [Life Science Washington Institute, April 2025] EXECUTIVE SUMMARY Q-Immune SaaS & Wet Lab Services Mission | https://www.lswinstitute.org/wp-content/uploads/2025/04/q-immune.pdf
4. [RocketReach, 2026] Q-Immune Information | https://rocketreach.co/q-immune-email-format_b680f0e8c9e6314c
5. [Brain & Behavior Research Foundation] Stephen Edward Paucha Smith, Ph.D. | Brain & Behavior Research Foundation | https://bbrfoundation.org/about/people/stephen-edward-paucha-smith-phd
6. [Stanford University] Stephen SMITH | Stanford University, Stanford | SU | Department of Molecular and Cellular Physiology | Research profile | https://www.researchgate.net/profile/Stephen-Smith-71
7. [Q-Immune] Platform | Advance CAR-T Insights Today, Q-Immune | https://www.qimmune.com/platform
8. [Pioneer Square Labs] T. A. McCann - Pioneer Square Labs | LinkedIn | https://www.linkedin.com/in/tamccann
9. [Grand View Research, 2024] CAR-T Therapy Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/car-t-cell-therapy-market
10. [MarketsandMarkets, 2023] AI in Drug Discovery Market | https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html
11. [Alliance for Regenerative Medicine, 2024] Annual Report & Sector Data | https://alliancerm.org/sector-report/
12. [Tufts Center for the Study of Drug Development, 2023] Cost of Developing a New Drug | https://csdd.tufts.edu/research/cost-of-developing-a-new-drug